| Published Application/Species/Dilution | Reference |
|---|
- immunohistochemistry (knockout validation); mouse; fig 3
| Rodriguez O, Lai E, Vissapragada S, Cromelin C, Avetian M, Salinas P, et al. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol. 2009;174:2051-60 pubmed publisher |
- western blot; mouse; 1:1000; fig 6
| Apostoli A, Skelhorne-Gross G, Rubino R, Peterson N, Di Lena M, Schneider M, et al. Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer. 2014;134:1055-66 pubmed publisher |
- immunoprecipitation; human
- immunocytochemistry; human; 1:200; fig 2
- western blot; human; fig 2
| Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, et al. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun. 2014;5:3393 pubmed publisher |
- immunoprecipitation; human; fig 3
- western blot; human; fig 1
| Choi M, Nakamura T, Cho S, Han X, Holland E, Qu J, et al. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson's disease models. J Neurosci. 2014;34:15123-31 pubmed publisher |
| Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73:2795-805 pubmed publisher |
| Hawse W, Sheehan R, Miskov-Zivanov N, Menk A, Kane L, Faeder J, et al. Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions. J Immunol. 2015;194:4615-9 pubmed publisher |
| Kuhla A, Thrum M, Schaeper U, Fehring V, Schulze-Topphoff U, Abshagen K, et al. Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. Apoptosis. 2015;20:500-11 pubmed publisher |
| Ugalde-Olano A, Egia A, Fernández-Ruiz S, Loizaga-Iriarte A, Zuñiga-García P, Garcia S, et al. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods. 2015;77:25-30 pubmed publisher |
| Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67:795-802 pubmed publisher |
| Hsu H, Cheng L, Ho T, Kuo W, Lin Y, Chen M, et al. Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour Biol. 2014;35:303-13 pubmed publisher |
| Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS ONE. 2014;9:e88291 pubmed publisher |
| Patel M, Gomez N, McFadden A, Moats-Staats B, Wu S, Rojas A, et al. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition. Mol Cancer Res. 2014;12:1610-20 pubmed publisher |
| Karapetis C, Jonker D, Daneshmand M, Hanson J, O'Callaghan C, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744-53 pubmed publisher |
| Yahiaoui O, Nunes J, Castanier C, Devillier R, Broussais F, Fabre A, et al. Constitutive AKT activation in follicular lymphoma. BMC Cancer. 2014;14:565 pubmed publisher |
| Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14:179 pubmed publisher |
| Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580-91 pubmed publisher |
| Miller K, Dieras V, Harbeck N, Andre F, Mahtani R, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32:1437-44 pubmed publisher |
| Bourgon R, Lu S, Yan Y, Lackner M, Wang W, Weigman V, et al. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res. 2014;20:2080-91 pubmed publisher |
| Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston R, et al. Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014;20:595-603 pubmed publisher |
| Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, et al. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol. 2013;44:829-36 pubmed publisher |
| Rodriguez S, Huynh-Do U. Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor. FASEB J. 2013;27:632-44 pubmed publisher |
| Locke F, Zha Y, Zheng Y, Driessens G, Gajewski T. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013;191:1677-85 pubmed publisher |
| Garcia-Carracedo D, Turk A, Fine S, Akhavan N, Tweel B, Parsons R, et al. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2013;19:6830-41 pubmed publisher |
| Tinker A, Ellard S, Welch S, Moens F, Allo G, Tsao M, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130:269-74 pubmed publisher |
| Teng Y, Manavalan T, Hu C, Medjakovic S, Jungbauer A, Klinge C. Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells. Toxicol Sci. 2013;131:71-83 pubmed publisher |
| Waniczek D, Snietura M, Młynarczyk-Liszka J, Pigłowski W, Kopec A, Lange D, et al. PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol. 2013;64:15-20 pubmed |
| Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. Int J Oncol. 2013;43:919-26 pubmed publisher |
| Wu R, Baker S, Hu T, Norman K, Fearon E, Cho K. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol. 2013;182:1391-9 pubmed publisher |
| Atreya C, Sangale Z, Xu N, Matli M, Tikishvili E, Welbourn W, et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013;2:496-506 pubmed publisher |
| Yip W, Choo C, Leong V, Leong P, Jabar M, Seow H. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS. 2013;121:954-66 pubmed publisher |
| Lee D, Do I, Choi K, Sung C, Jang K, Choi D, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25:131-9 pubmed publisher |
| Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 2012;7:1513-21 pubmed |
| Iqbal J, Thike A, Cheok P, Tse G, Tan P. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology. 2012;61:652-9 pubmed publisher |
| Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, DU Four S, et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol. 2012;41:1029-35 pubmed publisher |
| Laguë M, Paquet M, Fan H, Kaartinen M, Chu S, Jamin S, et al. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis. 2008;29:2062-72 pubmed publisher |
| Heindl M, Händel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 2012;142:1093-1096.e6 pubmed publisher |
| Pitter K, Galban C, Galban S, Tehrani O, Saeed-Tehrani O, Li F, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE. 2011;6:e14545 pubmed publisher |
| Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106:719-26 pubmed publisher |
| Waniczek D, Snietura M, Pigłowski W, Rdes J, Kopec A, Młynarczyk-Liszka J, et al. Analysis of PTEN expression in large intestine polyps and its relation to the recognized histopathological and clinical risk factors for cancer development in this location. Contemp Oncol (Pozn). 2012;16:310-5 pubmed publisher |
| Guertin D, Stevens D, Saitoh M, Kinkel S, Crosby K, Sheen J, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell. 2009;15:148-59 pubmed publisher |
| Snietura M, Jaworska M, Mlynarczyk-Liszka J, Goraj-Zając A, Piglowski W, Lange D, et al. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS ONE. 2012;7:e33396 pubmed publisher |
| Saal L, Gruvberger-Saal S, Persson C, Lövgren K, Jumppanen M, Staaf J, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. 2008;40:102-7 pubmed |
| Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol. 2011;19:173-83 pubmed publisher |
| Barbareschi M, Cuorvo L, Girlando S, Bragantini E, Eccher C, Leonardi E, et al. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch. 2012;461:129-39 pubmed publisher |
| Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman K, et al. Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int J Mol Sci. 2012;13:9980-91 pubmed publisher |
